@article{3c9b42660f19429db4e091ba67162ff6,
title = "Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study",
abstract = "In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected polymorphisms and treatment responses were characterized by competing risk methodology. Association analyses involved 821 individuals (317 for pharmacokinetics and 643 for treatment response). Models that included CYP2B6 516/ 983 genotype best predicted pharmacokinetics. Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants.",
author = "Ribaudo, {Heather J.} and Huan Liu and Matthias Schwab and Elke Schaeffeler and Michel Eichelbaum and Motsinger-Reif, {Alison A.} and Ritchie, {Marylyn D.} and Zanger, {Ulrich M.} and Acosta, {Edward P.} and Morse, {Gene D.} and Gulick, {Roy M.} and Robbins, {Gregory K.} and David Clifford and Haas, {David W.}",
note = "Funding Information: Financial support: This work was supported in part by the AIDS Clinical Trials Group (ACTG) funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (AI68636, AI38858, AI68634, and AI38855), and by virology laboratory contracts (201VC001 with Vanderbilt University, 200VC001 with the University of Alabama at Birmingham, and 200VC011 with Stanford University). Grant support included AI069439, RR000095, AI54999 (to D.W.H.), BRS-ACURE-06-00140-T001 (to G.D.M.), AI51966, RR024996 (to R.M.G.), AI069472, and AI062435 (to G.K.R.) as well as support from the Robert Bosch Foundation Stuttgart and the Hector Foundation, Weinheim, Germany. Study drugs were provided by Bristol-Myers Squibb and GlaxoSmithKline. Clinical research sites that participated in ACTG protocol 384 or A5095 and that collected DNA under protocol A5128 were supported by the following grants from the NIAID: AI069532, AI069484, AI069432, AI069450, AI069495, AI069434, AI069424, AI069439, AI69467, AI069423, AI069513, AI069477, AI069465, AI069419, AI069502, AI069474, AI069472, AI069501, AI069418, AI069494, AI069471, AI069511, AI069452, AI069428, AI069556, AI069415, AI32782, AI046376-05S4, AI46370, AI38858, AI34853, AI27661, AI25859, and AI069470.",
year = "2010",
month = sep,
day = "1",
doi = "10.1086/655470",
language = "English",
volume = "202",
pages = "717--722",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
number = "5",
}